


SUPPLEMENTARY DATA

Supplementary Figure 1. Representative CGM profiles of change in mean glucose over 4 days for individual participants.




CGM, continuous glucose monitoring; CANA, canagliflozin; PBO, placebo.


SUPPLEMENTARY DATA

Supplementary Figure 2. Proportion of participants with (A) any improvement in individual DTSQc treatment satisfaction scale score items and (B) less self-reported time spent in hyperglycemia and hypoglycemia at Week 18.

A.



B.



DTSQc, Diabetes Treatment Satisfaction Questionnaire change version; CANA, canagliflozin; PBO, placebo; SE, standard error; CI, confidence interval.

*95% CI for the odds ratio between canagliflozin and placebo excludes 1.